Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 476

1.

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F.

J Clin Oncol. 2017 Jul 7:JCO2017722975. doi: 10.1200/JCO.2017.72.2975. [Epub ahead of print]

PMID:
28686535
2.

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S.

Cancer Cell. 2017 Jul 10;32(1):88-100.e6. doi: 10.1016/j.ccell.2017.05.011. Epub 2017 Jun 29.

PMID:
28669490
3.

Nucleotide excision repair is a potential therapeutic target in multiple myeloma.

Szalat R, Samur MK, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, Wen K, Kumar S, Perini T, Calkins AS, Reznichenko E, Chauhan D, Tai YT, Shammas MA, Anderson KC, Fermand JP, Arnulf B, Avet-Loiseau H, Lazaro JB, Munshi NC.

Leukemia. 2017 Jun 7. doi: 10.1038/leu.2017.182. [Epub ahead of print]

PMID:
28588253
4.

Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Song Y, Li S, Ray A, Das DS, Qi J, Samur MK, Tai YT, Munshi N, Carrasco RD, Chauhan D, Anderson KC.

Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.172. [Epub ahead of print]

PMID:
28581522
5.

Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.

Bolli N, Barcella M, Salvi E, D'Avila F, Vendramin A, De Philippis C, Munshi NC, Avet-Loiseau H, Campbell PJ, Mussetti A, Carniti C, Maura F, Barlassina C, Corradini P, Montefusco V.

Cancer. 2017 May 23. doi: 10.1002/cncr.30777. [Epub ahead of print]

PMID:
28542843
6.

Management of ventilator associated pneumonia with a new antibiotic adjuvant entity (ceftriaxone+sulbactam+disodium edetate) - A novel approach to spare carbapenems.

Sathe P, Maddani S, Kulkarni S, Munshi N.

J Crit Care. 2017 May 15;41:145-149. doi: 10.1016/j.jcrc.2017.04.002. [Epub ahead of print]

PMID:
28535440
7.

Myeloma Minimal Residual Disease and Surrogacy-Reply.

Munshi N, Samur MK, Gregory W.

JAMA Oncol. 2017 May 11. doi: 10.1001/jamaoncol.2017.0404. [Epub ahead of print] No abstract available.

PMID:
28494053
8.

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC.

Clin Cancer Res. 2017 Apr 25. doi: 10.1158/1078-0432.CCR-17-0263. [Epub ahead of print]

PMID:
28442502
9.

Resident Macrophages: Near and Dear to Your Heart.

Munshi NV.

Cell. 2017 Apr 20;169(3):376-377. doi: 10.1016/j.cell.2017.04.002.

PMID:
28431239
10.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Bacco AD, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Apr 20. doi: 10.1158/1078-0432.CCR-16-2895. [Epub ahead of print]

PMID:
28428191
11.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM.

Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025.

12.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study.

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

PMID:
28379796
13.

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts.

Fernandez-Perez A, Munshi NV.

J Vis Exp. 2017 Mar 22;(121). doi: 10.3791/55456.

PMID:
28362413
14.

Phenotypically silent Cre recombination within the postnatal ventricular conduction system.

Bhattacharyya S, Bhakta M, Munshi NV.

PLoS One. 2017 Mar 30;12(3):e0174517. doi: 10.1371/journal.pone.0174517. eCollection 2017.

15.

Genomics of Multiple Myeloma.

Robiou du Pont S, Cleynen A, Fontan C, Attal M, Munshi N, Corre J, Avet-Loiseau H.

J Clin Oncol. 2017 Mar 20;35(9):963-967. doi: 10.1200/JCO.2016.70.6705. Epub 2017 Feb 13.

PMID:
28297630
16.

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC.

Clin Cancer Res. 2017 Mar 7. doi: 10.1158/1078-0432.CCR-16-2692. [Epub ahead of print]

PMID:
28270494
17.

The Promise of Cardiac Regeneration by In Situ Lineage Conversion.

Nam YJ, Munshi NV.

Circulation. 2017 Mar 7;135(10):914-916. doi: 10.1161/CIRCULATIONAHA.116.025830. No abstract available.

PMID:
28264888
18.

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, Munshi NC, Tai YT, Anderson KC.

Clin Cancer Res. 2017 Mar 1. doi: 10.1158/1078-0432.CCR-16-3192. [Epub ahead of print]

PMID:
28249894
19.

Modification of extraction method for community DNA isolation from salt affected compact wasteland soil samples.

Zaveri P, Patel R, Patel M, Sarodia D, Munshi NS.

MethodsX. 2017 Jan 17;4:63-67. doi: 10.1016/j.mex.2017.01.002. eCollection 2017.

20.

Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis.

Shapiro M, Nandi B, Gonzalez G, Prabhala RH, Mashimo H, Huang Q, Frank NY, Munshi NC, Gold JS.

Oncoimmunology. 2016 Dec 7;6(1):e1261776. doi: 10.1080/2162402X.2016.1261776. eCollection 2017.

PMID:
28197386

Supplemental Content

Loading ...
Support Center